



Extra CAS Registry Numbers(s): 15917-65-4
Molecular Formula: C₂₅H₂₇NO
Molecular Weight: 357.494
Accurate Mass: 357.209264
Percentage Composition: C 83.99%; H 7.61%; N 3.92%; O 4.48%
Metabolism: Metab. of Tamoxifen
Physical Description: Cryst. (2-propanol) (as hydrochloride)
Melting Point: Mp 174-176° (hydrochloride)

>>**Derivative:** 4"-Hydroxy

Synonym(s): 4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol, 9Cl. 4-Hydroxytamoxifen

CAS Registry Number: 68047-06-3
Extra CAS Registry Numbers(s): 65213-48-1 68392-35-8
Molecular Formula: C₂₆H₂₉NO₂
Molecular Weight: 387.521
Accurate Mass: 387.219829
Percentage Composition: C 80.59%; H 7.54%; N 3.61%; O 8.26%
Source/Synthesis: Metab. of Tamoxifen
Biological Use/Importance: Antioestrogen
Physical Description: Cryst. (EtOH)
Melting Point: Mp 140-143°
Other Data: There is some confusion concerning the allocation of CAS nos. to this and the *E*-isomer above. This is the pharmacol. active enantiomer, corresponding to *Z*-Tamoxifen

References:

- Aldrich Library of 13C and 1H FT NMR Spectra*, 1992, **2**, 575B, (*nmr*)
Precigoux, G. *et al.*, *Acta Cryst. B*, 1979, **35**, 3070, (*cryst struct*)
Binart, N. *et al.*, *Biochem. Biophys. Res. Commun.*, 1979, **91**, 812-818, (*metab*)
Robertson, D.W. *et al.*, *J.O.C.*, 1982, **47**, 2387, (*synth*)
Miller, R.B. *et al.*, *J.O.C.*, 1985, **50**, 2121, (*synth, bibl*)
Adam, H.K., *Curr. Clin. Pract. Ser.*, 1986, **31**, 83, (*rev, anal*)
Coe, P.L. *et al.*, *J.C.S. Perkin 1*, 1986, 475, (*synth*)
Goldberg, I. *et al.*, *J. Pharm. Sci.*, 1987, **76**, 259, (*struct*)
Al-Hassan, M., *Synth. Commun.*, 1987, **17**, 1247, (*synth*)
Legha, S.S., *Ann. Intern. Med.*, 1988, **109**, 219, (*rev*)
Buckley, M.M.-T. *et al.*, *Drugs*, 1989, **37**, 451, (*rev*)
Kikuta, C. *et al.*, *J. Pharm. Biomed. Anal.*, 1989, **4**, 329-337, (*Demethyltamoxifen, hplc*)
Potter, G.A. *et al.*, *J.O.C.*, 1990, **55**, 6184, (*synth*)
Robinson, S.P. *et al.*, *Drug Metab. Dispos.*, 1991, **19**, 36-43, (*Demethyltamoxifen*)
Catherino, W.H. *et al.*, *Drug Saf.*, 1993, **8**, 381, (*rev*)
Plowman, P.N., *Drugs*, 1993, **46**, 819, (*rev*)
Higa, G.M., *Am. J. Hosp. Pharm.*, 1994, **51**, 400, (*rev*)
Negwer, M., *Organic-Chemical Drugs and their Synonyms*, 7th edn., Akademie-Verlag, 1994, 10375, (*synonyms*)
Wiseman, H., *Tamoxifen: Molecular Basis of Use in Cancer Treatment and Prevention*, J. Wiley, Chichester, 1994, (*book*)
Olier-Reuchet, C. *et al.*, *Tet. Lett.*, 1995, **36**, 8221-8224, (*synth, deriv*)
Gauthier, S. *et al.*, *J.O.C.*, 1996, **61**, 3890-3893, (*synth, pmr, cmr, deriv*)
Manns, J.E. *et al.*, *J. Pharm. Biomed. Anal.*, 1998, **16**, 847-852, (*hplc*)
Osborne, C.K., *N. Engl. J. Med.*, 1998, **339**, 1609-1618, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 563
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, NOA600; TAD175